Provided by Tiger Trade Technology Pte. Ltd.

Viridian Therapeutics, Inc.

24.29
-0.2100-0.86%
Pre-market: 24.25-0.0400-0.16%04:31 EDT
Volume:906.30K
Turnover:22.04M
Market Cap:2.75B
PE:-7.02
High:24.75
Open:24.65
Low:24.07
Close:24.50
52wk High:34.29
52wk Low:13.18
Shares:113.29M
Float Shares:108.00M
Volume Ratio:0.57
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4579
EPS(LYR):-3.3245
ROE:-65.74%
ROA:-30.16%
PB:4.88
PE(LYR):-7.31

Loading ...

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Fortrea Holdings Inc. (FTRE)

TIPRANKS
·
Jun 29

U.S. Stocks on the Move-spacex, Charter

Reuters
·
Jun 29

US Stocks-wall St Climbs as Mideast Tensions Ease, Comcast Surges on Spin-off Plan

Reuters
·
Jun 29

Stock Market Today: Dow Jones, S&P 500 Futures Gain As Trump Admin Says US, Iran Will 'Stand Down'—Verizon, HP, Universe Pharmaceuticals In Focus

Benzinga Earnings
·
Jun 29

Viridian Therapeutics Shares up 10.8% Premarket After U.S. FDA Greenlights Co's Thyroid Eye Disease Drug

THOMSON REUTERS
·
Jun 29

Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday

Benzinga Earnings
·
Jun 29

Why Viridian Therapeutics (VRDN) Is Up 7.6% After FDA Clears First All‑Stage Thyroid Eye Drug

Simply Wall St.
·
Jun 29

Analysts Are Bullish on These Healthcare Stocks: Viridian Therapeutics (VRDN), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595)

TIPRANKS
·
Jun 28

US FDA Greenlights Viridian's Eye Disease Drug

Reuters
·
Jun 27

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

THOMSON REUTERS
·
Jun 27

Viridian’s VRDN-003 Thyroid Eye Disease Trial Reaches Completion, Resetting the Risk/Reward for Investors

TIPRANKS
·
Jun 26

Viridian Therapeutics (VRDN) Stock Could Be 84.84% Below Fair Value After Institutional Buying

Simply Wall St.
·
Jun 19

Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Viridian Therapeutics (VRDN)

TIPRANKS
·
Jun 17

Viridian Therapeutics shareholders elected Class II directors at annual meeting

Reuters
·
Jun 03

How Investors May Respond To Viridian Therapeutics (VRDN) Debt Repayment And WuXi Manufacturing Pact

Simply Wall St.
·
May 31

Viridian Therapeutics prepays Hercules loan, repays about $55.1 million

Reuters
·
May 29

Viridian Therapeutics management to present at Jefferies Global Healthcare Conference

Reuters
·
May 27

Viridian Therapeutics signs WuXi Biologics manufacturing pact for veligrotug commercial supply

Reuters
·
May 27

Viridian Therapeutics Inc - WuXi Biologics to Manufacture and Supply Veligrotug for Viridian Therapeutics - SEC Filing

THOMSON REUTERS
·
May 27

Evercore ISI Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)

TIPRANKS
·
May 15